Insulin

Anastasiou, Eleni; Paschou, Stavroula Α.

doi:10.1007/978-3-030-89243-2_14

Cited by 1 publication

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GDM was diagnosed based on a positive 75-g 2-h glucose tolerance test using the IADPSG (International Association of Diabetes and Pregnancy Study Groups) criteria [19]. Treatment with insulin was initiated based on the following: fasting blood glucose>90 mg/dl (5.0 mmol/l), 1-h postprandial glucose>130 mg/dl (7.4mmol/l) (more than 30% of measurements in 1 week), and/or evidence of macrosomia (FAC >75 th percentile) or polydramnios on fetal ultrasound [20]. A total of 192 women with GDM were finally included.…”

Section: Patientsmentioning

confidence: 99%

“…The patients had recorded their blood glucose values in diabetes diaries, which were evaluated at each visit. Insulin doses had been adjusted to maintain good glycemic control according to treatment targets (fasting blood glucose < 90mg/dl (5 mmol/l), that is, 1-h postprandial blood glucose ≤130mg/dl (7.8 mmol/l) [20]. Fetal ultrasound had been performed on a routine basis at inclusion, at 13, 21, and 32 weeks, and whenever necessary.…”

Section: Protocolmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of treatment with insulin detemir and NPH in women with gestational diabetes mellitus: glycemic control and pregnancy outcomes. A retrospective study

Kazakou,

Paschou,

Mitropoulou

et al. 2023

Hormones

Self Cite

View full text Add to dashboard Cite

Purpose The objective of this retrospective study was to compare glycemic control, pregnancy outcomes, and neonatal outcomes in women with gestational diabetes mellitus (GDM) treated with (a) insulin detemir and (b) insulin neutral protamine Hagedorn (NPH). Methods A total of 192 women with GDM were included in the analysis. Ninety-eight women received detemir, while 94 women received NPH. Data regarding medical history, glycemic control, and time and mode of delivery, as well as neonatal outcomes, were recorded. Results Baseline characteristics were comparable between the two groups. There were no differences with respect to the week of insulin initiation, total insulin dose, duration of insulin therapy, daily insulin dose/weight in early and late pregnancy, or the number of insulin injections per day. Maternal overall weight gain during pregnancy and weight gain per week did not differ either. The detemir group had slightly lower HbA1c levels at the end of gestation [median: det 5.2% (33 mmol/mol) vs NPH 5.4% (36 mmol/mol), p=0.035). There were no cases of hypoglycemia or allergic reactions in the two groups. There were also no differences regarding neonatal outcomes according to the available data, given that data in some cases were missing. Conclusion The use of insulin detemir was found to be equally effective and safe compared to NPH in women with GDM.

show abstract

Section: Patientsmentioning

confidence: 99%

Section: Protocolmentioning

confidence: 99%